Congenital fibrinogen deficiency is typically treated with replacement therapy. Historical treatment options have included fresh frozen plasma (FFP), 24-hour plasma, or cryoprecipitate, with cryoprecipitate being the most widely used. These products have several disadvantages:

  • They do not go through a virus inactivation/removal process.
  • They contain unnecessary proteins, increasing the risk of allergic reactions or adverse events.1
  • They must be thawed, prolonging time before infusion.

RiaSTAP is the first and only fibrinogen concentrate available in the US.

RiaSTAP is a fibrinogen concentrate that has undergone specific virus inactivation/removal to reduce the risk of exposure to infectious agents.

  1. Manco-Johnson MJ, DiMichele D, Castaman G, et al. for the Fibrinogen Concentrate Study Group. Pharmacokinetics and safety of fibrinogen concentrate. J Thromb Haemost. 2009; 7:2064-2069.

Important Safety Information

RiaSTAP®, Fibrinogen Concentrate (Human), is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

RiaSTAP is contraindicated in patients with known anaphylactic or severe systemic reactions to human plasma-derived products.

Monitor patients for early signs of anaphylaxis or hypersensitivity reactions and if necessary, discontinue administration and institute appropriate treatment. Thrombotic events have been reported in patients receiving RiaSTAP; weigh the benefits of administration versus the risks of thrombosis.

RiaSTAP is made from pooled human plasma. Products made from human plasma may contain infectious agents, eg, viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

The most serious adverse reactions observed are thrombotic episodes (pulmonary embolism, myocardial infarction, deep vein thrombosis) and anaphylactic reactions. The most common adverse reactions observed in clinical studies (frequency >1%) were fever and headache.

Please see full prescribing information for RiaSTAP.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.